Abstract: A method of camouflaging a tonal imperfection comprising the steps of: identifying a skin tone of a user comprising a tonal imperfection; instructing the user to select a pigmented cosmetic composition adapted to camouflage the tonal imperfection based on the user's skin tone; selecting the pigmented cosmetic composition; and selectively targeting and depositing the pigmented cosmetic composition substantially only onto the tonal imperfection; wherein the pigmented cosmetic composition comprises an average composition L* value of about 10 to about 40 units greater than an average skin L* value of the user. The pigmented cosmetic composition can comprise a particular set of L*C*h* values such that when deposited onto tonal imperfections, it can result in natural, flawless looking skin, while still remaining substantially undetectable to the naked eye.

Abstract: A method of camouflaging a tonal imperfection comprising the steps of: identifying a skin tone of a user comprising a tonal imperfection; instructing the user to select a pigmented cosmetic composition adapted to camouflage the tonal imperfection based on the user's skin tone; selecting the pigmented cosmetic composition; and selectively targeting and depositing the pigmented cosmetic composition substantially only onto the tonal imperfection; wherein the pigmented cosmetic composition comprises an average composition L* value of about 10 to about 40 units greater than an average skin L* value of the user. The pigmented cosmetic composition can comprise a particular set of L*C*h* values such that when deposited onto tonal imperfections, it can result in natural, flawless looking skin, while still remaining substantially undetectable to the naked eye.

Abstract: A method of camouflaging a tonal imperfection comprising the steps of: identifying a skin tone of a user comprising a tonal imperfection; instructing the user to select a pigmented cosmetic composition adapted to camouflage the tonal imperfection based on the user's skin tone; selecting the pigmented cosmetic composition; and selectively targeting and depositing the pigmented cosmetic composition substantially only onto the tonal imperfection; wherein the pigmented cosmetic composition comprises an average composition L* value of about 10 to about 40 units greater than an average skin L* value of the user. The pigmented cosmetic composition can comprise a particular set of L*C*h* values such that when deposited onto tonal imperfections, it can result in natural, flawless looking skin, while still remaining substantially undetectable to the naked eye.

Abstract: A management module of a managed computer is accessed via an out-or-band network. The management module communicates via a hypervisor with guest operating systems running in virtual machines on said managed computer.

Abstract: Methods and systems for synchronizing network configuration state tables between an operating system kernel and an attached ASIC switch device are disclosed. An instruction to update a target network configuration state table in either an operating system kernel or an attached ASIC switch device is received. Data from the target network configuration state table and data from a corresponding network configuration state table are retrieved. Values of data in the two tables are compared and an instruction is sent to update the target network configuration state table with one or more values from the corresponding network configuration state table.

Abstract: Methods and systems for synchronizing network configuration state tables between an operating system kernel and an attached ASIC switch device are disclosed. An instruction to update a target network configuration state table in either an operating system kernel or an attached ASIC switch device is received. Data from the target network configuration state table and data from a corresponding network configuration state table are retrieved. Values of data in the two tables are compared and an instruction is sent to update the target network configuration state table with one or more values from the corresponding network configuration state table.

Abstract: In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: A control logic secures access to an electronic system. The control logic comprises an initialization logic and an operational logic. The initialization logic allocates access rights individually among a plurality of hardware and/or operation elements in the electronic system and individually secures the plurality of hardware and/or operation elements with electronic and/or software-activated access. The operational logic responds to attempted access by a user to authenticate hardware and/or operation elements and enable operation of the hardware and/or operation elements upon authentication.

Abstract: A prefabricated reinforced brick panel has a plurality of bricks arranged in a spaced-apart array with mortar between the bricks. The array comprises a number of superimposed rows of bricks. The bricks in each row are staggered relative to the bricks in each adjacent row of bricks. Each brick has a number of vertical through holes extending between a top and a bottom of the brick. These through holes are aligned in the array and vertical reinforcing bars are inserted into aligned holes and extend between a top and a bottom of the panel. Two offset vertical reinforcing bars pass through each brick. Transverse reinforcing bars are mounted in the mortar between rows of bricks.

Abstract: Improved devices and methods for performing electroporation-mediated delivery agents to cells is described. The method includes positioning a first electrode and a second electrode such that an electrical signal passed between the first electrode and the second electrode passes through the cell. The method also includes passing an electrical signal between the first electrode and the second electrode, the electrical signal having a frequency greater than about 10 kHz. In one embodiment of the method, the electrical signal has a bipolar waveform. In another embodiment of the method, the electrodes are positioned at a treatment site, e.g., a tumor, for in vivo delivery of an agent.

Abstract: In one embodiment the present invention provides a method for identity verification comprising the steps of: (a) comparing at least one first spoken voice print of a user speaking at least one piece of personal data against a first stored voice print of the user speaking said at least one piece of personal data; (b) comparing at least one second spoken voice print of the user speaking at least one piece of travel data against a second stored voice print of the user speaking said piece of travel data; and (c) determining if the user is a given individual based the results of step (a) and step (b).

Abstract: In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: The present invention describes an in vivo method, using pulsed electric field to deliver therapeutic agents into cells of the skin and muscle for local and systemic treatments. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: The present invention describes an in vivo method, using pulsed electric field to deliver therapeutic agents into cells of the skin and muscle for local and systemic treatments. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: In one embodiment the present invention provides a method for identity verification comprising the steps of: (a) comparing at least one first spoken voice print of a user speaking at least one piece of personal data against a first stored voice print of the user speaking said at least one piece of personal data; (b) comparing at least one second spoken voice print of the user speaking at least one piece of travel data against a second stored voice print of the user speaking said piece of travel data; and (c) determining if the user is a given individual based the results of step (a) and step (b).

Abstract: The present invention describes an in vivo method, using pulsed electric field to deliver therapeutic agents into cells of the skin and muscle for local and systemic treatments. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: The present invention describes an in vivo method, using pulsed electric field to deliver therapeutic agents into cells of the skin and muscle for local and systemic treatments. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

Abstract: A mileage and fuel purchase monitoring device for vehicles including a data collecting system that is connected with an odometer of a truck or other motor vehicle. The data collecting system is preferably secured to a dashboard of the truck for easy access by the driver. The data collecting system is provided with a keyboard and a display for entering relevant information related to a planned trip to be made.

Abstract: A prefabricated modular wall element (20) comprises a precast reinforced concrete wall panel (21) having a front face (24). A plurality of spaced-apart individual slabs (33) of stone or brick are partially embedded in the front face (24) of the panel (21) during casting of the panel (21) and project outwardly of the front face (24) with channels being formed between the slabs (33). The slabs are arranged on the front face (24) such that the front face (24) simulates a wall constructed of stone. A pair of spaced-apart support legs (38) are provided at a bottom (27) of the wall panel (21) for keying into a concrete foundation (42) to support the wall element (1) in an upright.